In rodent NASH, CCR2/5 inhibition significantly reduced circulating Ly6C+ monocytes and hepatic monocyte-derived macrophages, alongside reduced hepatic inflammation and fibrosis. The gene discussed is CCR2; the disease is metabolic dysfunction-associated steatohepatitis.